Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2005
06/02/2005US20050118178 Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy
06/02/2005US20050118177 Method for the improvement of neuronal regeneration
06/02/2005US20050118176 Inhibiting binding of interleukin-4 (IL-4) to an IL-4 Receptor; suppressing an IL-4-dependent immune or inflammatory response in a mammal
06/02/2005US20050118175 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
06/02/2005US20050118172 Humanized antibody CAMPATH-1H administered with steroid (hydrocortisone)
06/02/2005US20050118168 Administering a compound which binds to a C-type lectin on the surface of a dendritic cell, with the proviso that the C-type lectin is not the DEC-205 receptor
06/02/2005US20050118166 Inhibiting activation by CD40 ligand (CD40L) of cells bearing CD40 on the cell surface, other than B cells, by contacting with an agent that inhibits the interaction between CD40L and the cells; treating autoimmune diseases
06/02/2005US20050118162 Treatment of micro-organism infection
06/02/2005US20050118160 Inhibits delayed vascular rejection; makes organs less vulnerable to rejection after transplantation
06/02/2005US20050118159 recombinant DNA molecules that express homogenous lysostaphin and host cells transformed with these DNA molecules
06/02/2005US20050118158 Pharmacological vitreolysis
06/02/2005US20050118157 Treatment of central nervous system damage
06/02/2005US20050118156 Storage-stable fibrin sealant
06/02/2005US20050118155 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/02/2005US20050118154 Antitumor effect of mutant Bik
06/02/2005US20050118150 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
06/02/2005US20050118149 Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression
06/02/2005US20050118138 Method of treatment using interferon-tau
06/02/2005US20050118137 Oral administration, for modulating the IL-10/IL-12 blood ratio to treat autoimmune disorders and viral infections
06/02/2005US20050118117 Methods for identifying risk of melanoma and treatments thereof
06/02/2005US20050118114 Pulmonary insulin crystals
06/02/2005US20050118112 Neutralizing lipoarabinomannan physiological effects
06/02/2005US20050118109 Method for treating lung diseases associated with ventilation-perfusion mismatches
06/02/2005US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt
06/02/2005US20050118099 Thiol-mediated drug attachment to targeting peptides
06/02/2005DE10352602A1 Kosmetisches oder therapeutisches Kombinationspräparat Cosmetic or therapeutic combination product
06/02/2005DE10163098B4 Verfahren zur Hemmung der Replikation von Viren A method of inhibiting the replication of viruses
06/02/2005CA2547083A1 A method of inducing melanogenesis in humans with mc1r variant alleles
06/02/2005CA2546836A1 Immunization against chlamydia infection
06/02/2005CA2546794A1 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
06/02/2005CA2546406A1 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
06/02/2005CA2546383A1 Rescue agents for treating botulinum toxin intoxications
06/02/2005CA2545944A1 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
06/02/2005CA2545923A1 Excipients in drug delivery vehicles
06/02/2005CA2545915A1 Minimization of drug oxidation in drug irradiated excipients formulations
06/02/2005CA2545912A1 Autologous treatment of degenerated disc with cells
06/02/2005CA2545855A1 Alpha 1-antitrypsin compositions and treatment methods using such compositions
06/02/2005CA2545800A1 Surfactant-based gel as an injectable, sustained drug delivery vehicle
06/02/2005CA2545726A1 Use of interferon tau for the treatment of obesity and for promotion of weight loss
06/02/2005CA2545615A1 Methods and reagents for the treatment of inflammatory disorders
06/02/2005CA2545219A1 Efficient introduction of an aerosol into a ventilator circuit
06/02/2005CA2545198A1 Skeletal muscle-derived cells and methods related thereto
06/02/2005CA2545034A1 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
06/02/2005CA2544573A1 Combinations useful for the treatment of neuronal disorders
06/02/2005CA2544234A1 Fibres embedded in a glassy protein
06/02/2005CA2540986A1 Therapeutic use of factor xi
06/02/2005CA2538342A1 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
06/02/2005CA2536042A1 Medical implants and anti-scarring agents
06/01/2005EP1536234A2 Soluble CTLA4 mutant molecules and uses thereof
06/01/2005EP1536013A1 Dna sequence useful in diagnosing hepatitis and polypeptide encoded thereby
06/01/2005EP1536010A1 Preventives/remedies for cancer
06/01/2005EP1536009A1 Hla-a24-restricted cancer antigen peptide
06/01/2005EP1536008A1 2’,5’-OLIGOADENYLATE PHOSPHODIESTERASE
06/01/2005EP1535929A2 Megakaryocyte stimulating factors
06/01/2005EP1535625A1 Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
06/01/2005EP1535624A1 Chronic myeloid leukemia (cml) therapy
06/01/2005EP1535623A1 Renal cell carcinoma treatment
06/01/2005EP1535622A1 Melanoma therapy
06/01/2005EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
06/01/2005EP1534861A1 Sirna-mediated gene silencing with viral vectors
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534834A2 Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof
06/01/2005EP1534825A2 Human analogs of murine deubiquitinating protease genes
06/01/2005EP1534822A1 Immunotherapy using modulators of notch signalling
06/01/2005EP1534751A2 Ocular gene therapy
06/01/2005EP1534750A2 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor
06/01/2005EP1534749A2 Variant integrin polypeptides and uses thereof
06/01/2005EP1534748A2 Fusion proteins and methods of producing same
06/01/2005EP1534747A2 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
06/01/2005EP1534745A2 A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish
06/01/2005EP1534744A1 Altered insulin-like growth factor binding proteins
06/01/2005EP1534743A1 Scorpion peptide as hypotensive agent
06/01/2005EP1534737A2 Peptide antagonists of tgf-beta family members and therapeutic uses thereof
06/01/2005EP1534730A2 Modified transferin-antibody fusion proteins
06/01/2005EP1534729A2 Variants of nedd4l associated with hypertension and viral budding
06/01/2005EP1534512A1 Coated particles, methods of making and using
06/01/2005EP1534334A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers
06/01/2005EP1534331A2 Membrane associated tumor endothelium markers
06/01/2005EP1534325A2 Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
06/01/2005EP1534324A2 Tumor specific oligosaccharide epitopes and use thereof
06/01/2005EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis
06/01/2005EP1534321A1 Methods of use of compounds with preptin function
06/01/2005EP1534320A2 Apolipoprotein l-i for the treatment or diagnosis of trypanosomal diseases
06/01/2005EP1534319A2 Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
06/01/2005EP1534318A2 Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
06/01/2005EP1534317A2 N-terminally truncated galectin-3 and antibodies for treating cancer
06/01/2005EP1534316A2 Glycopeptide antibiotics and semisynthetic derivatives thereof and their use as antiviral agents
06/01/2005EP1534315A2 Increasing of the resorption of substances via skin and mucous membranes
06/01/2005EP1534314A1 A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
06/01/2005EP1534313A2 Ophthalmologic irrigation solutions and method
06/01/2005EP1534310A2 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
06/01/2005EP1534309A2 Parathyroid hormone antagonists and uses thereof
06/01/2005EP1534308A2 Peptides with growth inhibitory action
06/01/2005EP1534306A2 Defensins: use as antiviral agents
06/01/2005EP1534299A2 Methods for treating psychosis associated with interferon-alpha therapy
06/01/2005EP1534243A1 Treating alzheimers using delipidated protein particles
06/01/2005EP1534242A2 Buccal, polar or non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
06/01/2005EP1534236A1 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
06/01/2005EP1534074A2 Combination therapy for the treatment of obesity
06/01/2005EP1483397A4 Oligomeric molecules and uses thereof
1 ... 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 ... 3163